BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock enjoyed a major increase of 25.6% on 1/8/24. The shares closed at $7.65. Moreover, trading volume in this advance was exceptionally high at 286% of normal. Relative to the market the stock has been weak over the last nine months but has risen 25.6% during the last week.
Current PriceTarget Research Rating
BCRX is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.